iShares Biotechnology ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

Amesite

Meiwu Tech

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

CODX

SBIO

Co-Diagnostics Inc. (CODX) has developed a Bundibugyo virus assay for rapid detection amid escalating Ebola outbreak alerts. Following WHO's emergency declaration, the company emphasizes the importance of decentralized diagnostics and rapid PCR testing. CEO Dwight Egan highlighted the need for quick mobilization in response to infectious diseases, shaped by lessons from COVID-19. The company is prepared for collaboration on future assay development. CODX shares are currently trading at $2.07, up 51.09%.

nasdaq

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Nasdaq

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

513700

159859

ARKG

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Proshares UltraShort Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

VG Health

BlackRock, Inc.

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Huaan Hang Seng Biotech ETF

Ark Genomic Revolution ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

SVRA

Savara's corporate presentation highlighted Phase 3 IMPALA-2 data for MOLBREEVI, showing significant improvement in DLCO% at Week 24 and sustained gains at Week 48 versus placebo. Patient-reported outcomes also improved at Week 24. The FDA BLA PDUFA date for MOLBREEVI is set for Nov. 22, 2026, with the drug still unapproved.

PUBT

Savara

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

SLXNW

SLXN

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

Silexion Therapeutics

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

MEDP

Medpace Holdings shareholders approved charter amendments to remove supermajority voting requirements and limits on calling special meetings during the annual meeting on May 15, 2026. The changes will take effect on May 18, 2026. Additionally, shareholders owning at least 25% of voting power can now call special meetings, subject to certain conditions. A non-binding proposal for calling special meetings did not pass.

Medpace

iShares Genomics Immunology and Healthcare ETF

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara presented 48-week data from the Phase 3 IMPALA-2 trial at the ATS International Conference 2026, showing long-term efficacy and safety of molgramostim in aPAP. Results indicated sustained lung function improvement and quality of life in patients on molgramostim, with those switching from placebo also showing benefits. The safety profile was consistent with previous trials, and 160 out of 164 enrolled patients completed the study, indicating strong retention.

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP

The latest Bank of America Fund Manager Survey indicates a record increase in equity allocation among investment professionals, alongside a significant drop in cash levels. This trend follows a strong stock market rally, primarily driven by a few tech sectors, raising concerns about sustainability and the underlying economic fundamentals.

- Bank of America's latest Fund Manager Survey indicates a historic rise in equity allocation among Wall Street investment professionals.  
- This surge is attributed to a significant rally in stocks, particularly in memory, chip, and AI sectors, driven by offside positioning and a historic squeeze.  
- Investors are hopeful that increased debt-funded capital expenditures will continue to benefit these sectors, despite uncertainties regarding their return on investment.

ZeroHedge

VG Growth

iShares Core S&P 500

ProShares Ultra QQQ

Amplify Online Retail ETF

Direxion Semicon Bull 3X

VG S&P 500

iShares Expanded Tech Software Sector ETF

VG S-Cp Grw

VanEck Retail ETF

Invesco QQQ Trust

iShares Semiconductor ETF

SPDR S&P Software

Proshares UltraPro QQQ

VanEck Semiconductor ETF

Schw Us L-Cp Grw

Global X Internet

ISHRS Russ 1000 Growth

SPDR S&P 500

ProShares Online Retail

First Trust NASDAQ-100 Equal Weighted

Global X E-commerce ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

"Sell Signal" Triggered In Latest BofA Fund Manager Survey: Record Surge In Equity Allocation, Plunge In Cash Levels

Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics for approximately $14.17 million, reducing its stake to 966,609 shares valued at $17.52 million. Despite this sale, Dyne's stock has risen nearly 40% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for rare muscle diseases and has a strong cash position of $972.2 million, funding operations into 2028. Investors are advised to consider other stocks as Dyne was not included in a recent top 10 list by The Motley Fool.

Dyne Therapeutics

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

OCUL

Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1,504,880 shares for an estimated $14.34 million. The fund's reported assets fell by $18.27 million due to share sales and price changes. Ocular's recent performance has been mixed, with revenue growth lagging and net losses widening, despite positive clinical trial data. Investors are advised to consider other stocks, as Ocular was not included in a recent top investment list.

Ocular Therap

Netflix

NVIDIA

NVIDIA Corporation

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

ENVB

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.

Enveric Biosciences

iShares Biotechnology ETF(IBB.US)

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Medpace Holdings shareholders approve charter amendments removing supermajority voting requirements

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP

"Sell Signal" Triggered In Latest BofA Fund Manager Survey: Record Surge In Equity Allocation, Plunge In Cash Levels

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.